Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan

Vaccine

Volumn 22, Issue 29-30, 2004, Pages 4062-4068

  Maitta, Robert W ^a   Datta, Kausik ^a   Pirofski, Liise Anne ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

Antibody mediated immunity; Cryptococcus neoformans; Mimotope vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; ANTISERUM; DIPHTHERIA TOXOID; GLUCURONOXYLMANNAN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PEPTIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CRYPTOCOCCUS NEOFORMANS; GENE LOCUS; IMMUNIZATION; LETHAL DOSE; MEDIATOR RELEASE; MOUSE; MOUSE STRAIN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTECTION; SURVIVAL; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GENES, IMMUNOGLOBULIN; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN M; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; POLYSACCHARIDES; TETANUS TOXOID;

EID: 4444276295     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.060     Document Type: Article

References (39)

1. Dromer F., Charreire J., Contrepois A., Carbon C., Yeni P. Protection of mice against experimental cryptococcosis by an anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 55:1987;749-752
2. Sanford J.E., Lupan D.M., Schlageter A.M., Kozel T.R. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun. 58(6):1990;1919-1923
3. Fleuridor R., Zhong Z., Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis. 178:1998;1213-1216
4. Mukherjee J., Scharff M.D., Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun. 60:1992;4534-4541
5. Casadevall A., Cleare W., Feldmesser M., Glatman-Freedman A., Goldman D.L., Kozel T.R., et al. Characterization of a murine monoclonal antibody to C. neoformans polysaccharide which is a candidate for human therapeutic studies. Antimicrob Agents Chemother. 42:1998;1437-1446
6. DeShaw M., Pirofski L. Antibodies to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan are ubiquitous in the serum of HIV+ and HIV- individuals. Clin Exp Immunol. 99:1995;425-432
7. Zhong Z., Pirofski L. Opsonization of Cryptococcus neoformans by human anti-glucuronoxylomannan antibodies. Infect Immun. 64:1996;3446-3450
8. Zhong Z., Pirofski L. Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Diag Lab Immunol. 5:1998;58-64
9. Pirofski L., Lui R., DeShaw M., Kressel A.B., Zhong Z. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun. 63:1995;3005-3014
10. Zhang H., Zhong Z., Pirofski L. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect Immun. 65:1997;1158-1164
11. Fleuridor R., Lees A., Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol. 166:2001;1087-1096
12. Maitta R.W., Datta K., Lees A., Sims Belouski S., Pirofski L.A. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun. 72(1):2004;196-208
13. Mendez M.J., Green L.L., Corvalan J.R., Jia X.C., Mayrard-Currie C.E., Yang X.D., et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Gen. 15(2):1997;146-156
14. Buchwald U.K., Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: the past. Curr Pharm Des. 9(12):2003;945-968
15. Teitelbaum R., Glatman-Freedman R., Chen B., Robbins J.B., Urare E., Casadevall A., et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA. 95:1998;15688-15693
16. Stanton B.F., Baltimore R.S., Shedd D.G. Effects of route and time of administration of antiserum on protection of mice from lethal infection due to group B Streptococcus type III. Infect Immun. 31(1):1981;391-395
17. Yoo E.M., Wims L.A., Chan L.A., Morrison S.L. Human IgG2 can form covalent dimers. J Immunol. 170(6):2003;3134-3138
18. Aalberse R.C., Schuurman J., Van Ree R. The apparent monovalency of human IgG4 is due to bispecificity. Int Arch Allergy Immunol. 118(2-4):1999;187-189
19. Cooper L.J., Schimenti J.C., Glass D.D., Greenspan N.S. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J Immunol. 146(8):1991;2659-2663
20. McLean G.R., Torres M., Elguezabal N., Nakouzi A., Casadevall A. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol. 169:2002;1379-1386
21. Garcia-Ojeda P.A., Monser M.E., Rubenstein L.J., Jennings H.J., Stein K.E. Murine immune response to Neisseria meningitidis Group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent conjugate vaccine. Infect Immun. 68:1999;239-246
22. Casadevall A., Scharff M.D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 38(8):1994;1695-1702
23. Casadevall A., Scharff M.D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 21(1):1995;150-161
24. Taborda C., Casadevall A. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol. 166:2001;2100-2107
25. Devi S.J. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine. 14(9):1996;841-844
26. Diamond M.S., Sitati E.M., Friend L.D., Higgs S., Shrestha B., Engle M. A critical role for induced IgM in the protection against West Nile Virus infection. J Exp Med. 198(12):2003;1853-1862
27. Harada Y., Muramatsu M., Shibata T., Honjo T., Kuroda K. Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J Exp Med. 197(12):2003;1779-1785
28. Casadevall A., Pirofski L.A. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 24(9):2003;474-478
29. Burns T., Zhong Z., Steinitz M., Pirofski L.A. Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide. Infect Immun. 71(12):2003;6775- 6783
30. Friedrich I., Silber R.E., Baumann B., Fischer C., Holzheimer R.G. IgM-enriched immunoglobulin preparation for immunoprophylaxis in cardiac surgery. Eur J Med Res. 7(12):2002;544-549
31. Batzloff M.R., Hayman W.A., Davies M.R., Zeng M., Pruksakorn S., Brardt E.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis. 187(10):2003;1598-1608
32. Granoff D.M., Shackelford P.G., Holmes S.J., Lucas A.H. Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group. J Clin Invest. 91(3):1993;788-796
33. Lucas A.H., Granoff D.M. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates. J Immunol. 154:1995;4195-4202
34. Puumalainen T., Dagan R., Wuorimaa T., Zeta-Capeding R., Lucero M., Ollgren J., et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J. 22(2):2003;141-149
35. Sigurdardottir S.T., Ingolfsdottir G., Davidsdottir K., Gudrason T., Kjartansson S., Kristinsson K.G., et al. Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine. Pediatr Infect Dis J. 21(6):2002;548-554
36. May R.J., Beenhouwer D.O., Scharff M.D. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. J Immunol. 171(9):2003;4905-4912
37. van Ojik H.H., Bevaart L., Dahle C.E., Bakker A., Jansen M.J., van Vugt M.J., et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 63(17):2003;5595-5600
38. Bozza S., Gaziano R., Lipford G.B., Montagnoli C., Bacci A., Di Francesco P., et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 4(13):2002;1281-1290
39. Souza M.C., Correa M., Almeida S.R., Lopes J.D., Camargo Z.P. Immunostimulatory DNA from Paracoccidioides brasiliensis acts as T-helper 1 promoter in susceptible mice. Scand J Immunol. 54(4):2001;348-356